March 3, 2026Cancer Immunology Immunotherapy0 citationsOpen Access

Dual targeting of CD155 augments the antitumor efficacy of ROR1-CAR-T cells in ovarian cancer

YYYingjun YeShanghai First Maternity and Infant Hospital TLTingwei LiuShanghai First Maternity and Infant Hospital CCChao Cheng

Key Points

Enhanced tumoricidal activity observed with bispecific CAR-T targeting CD155 and ROR1, indicating better efficacy.
Durable effects highlight the potential of dual-targeted therapies for improved outcomes in ovarian cancer.
Analysis involved a bispecific CAR-T approach focused on dual targeting, demonstrating elevated therapeutic potential.
Findings suggest that targeting CD155 may enable more effective strategies against ovarian cancer tumors.

Abstract

CD155 emerges as a promising therapeutic target for CAR-T therapy in OC. The bispecific CAR-T construct that co-targets CD155 and ROR1 demonstrates superior and durable tumoricidal activity, offering new perspectives on OC targeted therapy.

问 AI

Bookmark

View Full Paper